TY - JOUR
T1 - Founder and recurrent mutations in BRCA1 and BRCA2 genes in Latin American Countries
T2 - State of the art and literature review
AU - Ossa, Carlos Andrés
AU - Torres, Diana
N1 - Publisher Copyright:
© AlphaMed Press 2016.
PY - 2016/7
Y1 - 2016/7
N2 - Background. Numerous epidemiological factors affect the probability of developing breast or ovarian cancer, but no predictor is as determinant as inheriting a mutation in BRCA1 or BRCA2. The concept of the founder effect explains the reduced genetic variability in some populations, according to the theory thatnewpopulations can beformedfrom a reduced number of individuals, so the new population would carry only a small fraction of the genetic variability of the original population. The main purpose of this review is to provide an update on the state of the art in founder mutations and some recurrent mutations that have recently been described in Latin America. Methods. A literature search was performed in the electronic databases of PUBMED, EMBASE, LILACS, and BIREME using the terms BRCA1, BRCA2, founder mutation, Latin American population, andHispanic. Sixty-twopaperswereidentified, ofwhich 38wereconsideredrelevant for this review. Eachresult is shown per country. Results. In Latin America, clear founder effects have been reported in Mexico (BRCA1 del exons 9-12), Brazil (BRCA1 5382insC and BRCA2 c.156_157insAlu), and Colombia (BRCA1 3450del4, A1708E, and BRCA2 3034del4) and in Latinas residing in Southern California (BRCA1 185delAG, IVS5+1G>A, S955x, and R1443x). Of these, mutation BRCA1 3450del4 has also been reported in Brazil and Chile, whereas mutation BRCA2 3034del4 has been reported in Argentina and Peru.These data support the idea that although most Hispanic populations are the result of a mixture between Europeans, Africans, and Amerindians, the relative proportion of each genetic component varies throughout the Hispanic populations, making it necessary to identify the mutations characteristic of each population to generate mutation profiles adjusted to each one of them. Conclusion. In Latin American countries, and even among regions of the same country, there is great heterogeneity of ancestors. Therefore, Latinas should not be analyzed like other population groups without taking into account their genetic ancestry. The presence of founder mutations in specific population groups represents a cost-effective analysis. The importance of determining the founder mutations liesmainly in the decrease in costs. If we manage to decrease costs, screenings could be offered more widely and cover a larger number of women.
AB - Background. Numerous epidemiological factors affect the probability of developing breast or ovarian cancer, but no predictor is as determinant as inheriting a mutation in BRCA1 or BRCA2. The concept of the founder effect explains the reduced genetic variability in some populations, according to the theory thatnewpopulations can beformedfrom a reduced number of individuals, so the new population would carry only a small fraction of the genetic variability of the original population. The main purpose of this review is to provide an update on the state of the art in founder mutations and some recurrent mutations that have recently been described in Latin America. Methods. A literature search was performed in the electronic databases of PUBMED, EMBASE, LILACS, and BIREME using the terms BRCA1, BRCA2, founder mutation, Latin American population, andHispanic. Sixty-twopaperswereidentified, ofwhich 38wereconsideredrelevant for this review. Eachresult is shown per country. Results. In Latin America, clear founder effects have been reported in Mexico (BRCA1 del exons 9-12), Brazil (BRCA1 5382insC and BRCA2 c.156_157insAlu), and Colombia (BRCA1 3450del4, A1708E, and BRCA2 3034del4) and in Latinas residing in Southern California (BRCA1 185delAG, IVS5+1G>A, S955x, and R1443x). Of these, mutation BRCA1 3450del4 has also been reported in Brazil and Chile, whereas mutation BRCA2 3034del4 has been reported in Argentina and Peru.These data support the idea that although most Hispanic populations are the result of a mixture between Europeans, Africans, and Amerindians, the relative proportion of each genetic component varies throughout the Hispanic populations, making it necessary to identify the mutations characteristic of each population to generate mutation profiles adjusted to each one of them. Conclusion. In Latin American countries, and even among regions of the same country, there is great heterogeneity of ancestors. Therefore, Latinas should not be analyzed like other population groups without taking into account their genetic ancestry. The presence of founder mutations in specific population groups represents a cost-effective analysis. The importance of determining the founder mutations liesmainly in the decrease in costs. If we manage to decrease costs, screenings could be offered more widely and cover a larger number of women.
KW - BRCA1
KW - BRCA2
KW - Breast cancer
KW - Hereditary cancer
KW - Hispanics
KW - Latin America
UR - http://www.scopus.com/inward/record.url?scp=84978488585&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2015-0416
DO - 10.1634/theoncologist.2015-0416
M3 - Review article
C2 - 27286788
AN - SCOPUS:84978488585
SN - 1083-7159
VL - 21
SP - 832
EP - 839
JO - Oncologist
JF - Oncologist
IS - 7
ER -